ID
SIOX

Integral Derivatives’s Sio Gene Therapies Inc. Common Stock SIOX Stock Holding History

Integral Derivatives’s Portfolio SIOX Stock Details SIOX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-2,063
Closed -$87K – 1088
2017
Q4 		$87K Buy
2,063
+163
+9% +$7.31K ﹤0.01% 1044
2017
Q3 		$105K Buy
+1,900
New +$321K ﹤0.01% 1071

Other funds holding SIOX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ARTA
A.R.T. Advisors New York $1.79M AUM 57.47% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Integral Derivatives's SIOX Position: Q4 2017 in Review

Integral Derivatives sold out of Sio Gene Therapies Inc. Common Stock (SIOX) in Q4 2017, closing a stake of 2,109 shares — an estimated $94.6K sold.

Integral Derivatives first reported a position in SIOX in Q3 2017 and held it in 1 quarter. The position peaked at $116K in Q3 2017. 104 funds tracked by Wall St. Rank hold SIOX as of Q4 2017.

  • Integral Derivatives reported no remaining Sio Gene Therapies Inc. Common Stock position as of Q4 2017 after selling out during the quarter.
  • Integral Derivatives sold 2,109 Sio Gene Therapies Inc. Common Stock shares in Q4 2017, an estimated $94.6K.
  • Integral Derivatives first reported a position in Sio Gene Therapies Inc. Common Stock in Q3 2017 and held it in 1 quarter.
  • Integral Derivatives's Sio Gene Therapies Inc. Common Stock position peaked at $116K in Q3 2017.
  • 104 funds tracked by Wall St. Rank held Sio Gene Therapies Inc. Common Stock as of Q4 2017.

Based on Integral Derivatives's 13F filing for Q4 2017, filed 14 Feb 2018.